RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

• Published in: bioRxiv
• Main Authors: Carr, Ryan M, Vorobyev, Denis, Lasho, Terra, Marks, David L, Tolosa, Ezequiel J, Vedder, Alexis, Almada, Luciana, Yurchenko, Andrey, Padioleau, Ismael, Alver, Bonnie, Coltro, Giacomo, Binder, Moritz, Safgren, Stephanie L, Horn, Isaac, You, Xiaona, Droin, Nathalie, Solary, Eric, Balasis, Maria E, Berger, Kurt, Pin, Christopher, Witzig, Thomas, Ajinkya Buradkar, Graf, Temeida, Valent, Peter, Mangaonkar, Abhishek A, Robertson, Keith D, Howard, Matthew T, Kaufmann, Scott H, Fernandez-Zapico, Martin E, Geissler, Klaus, Padron, Eric, Zhang, Jing, Nikolaev, Sergey, Patnaik, Mrinal M
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 26.12.2019
• Subjects: Chronic myelomonocytic leukemia; Gene expression; Hemopoiesis; Kinases; Leukemia; Lysine; Malignancy; Methyltransferase; Monocytosis; Mutation; Myelomonocytic leukemia; Phenotypes; Polo-like kinase 1; Ribonucleic acid; RNA; Xenografts
• DOI: 10.1101/2019.12.23.874487

Chronic myelomonocytic leukemia (CMML) is an aggressive hematological malignancy with limited treatment options. Whole exome (WES) and targeted sequencing of several independent cohorts of CMML patients, comparing dysplastic (dCMML) to proliferative (pCMML) CMML, as well as paired chronic phase disease and acute leukemic transformation (LT), associate acquisition of oncogenic RAS pathway mutations, the most common being NRASG12D, with aggressive disease and with disease progression. Using patient derived progenitor colony assays and a NRASG12D-Vav-Cre mouse model, we further demonstrate the role of mutant RAS signaling in driving and maintaining pCMML phenotype. RNA-sequencing links RAS pathway mutations with an increased expression of genes encoding the mitotic checkpoint kinases PLK1 and WEE1. Further, we dmeoinstrated that non-mutated lysine methyltransferase KMT2A (MLL1) acts as mediator of NRAS-induced PLK1 and WEE1 expression. Finally, we demonstrate the translational value of our findings by showing that pharmacological PLK1 inhibition decreases monocytosis and hepatosplenomegaly while improving hematopoiesis in RAS mutant patient-derived xenografts. Hence, we define severe CMML as oncogenic RAS pathway-enriched malignancies, with a unique gene expression profile regulated by KMT2A, amenable to therapeutic intervention.